DK1147134T3 - New potassium channels and genes encoding these potassium channels - Google Patents

New potassium channels and genes encoding these potassium channels

Info

Publication number
DK1147134T3
DK1147134T3 DK00901048T DK00901048T DK1147134T3 DK 1147134 T3 DK1147134 T3 DK 1147134T3 DK 00901048 T DK00901048 T DK 00901048T DK 00901048 T DK00901048 T DK 00901048T DK 1147134 T3 DK1147134 T3 DK 1147134T3
Authority
DK
Denmark
Prior art keywords
potassium channels
genes encoding
channels
new
kcnq4
Prior art date
Application number
DK00901048T
Other languages
Danish (da)
Inventor
Thomas J Jentsch
Original Assignee
Neurosearch As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch As filed Critical Neurosearch As
Application granted granted Critical
Publication of DK1147134T3 publication Critical patent/DK1147134T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)

Abstract

This invention relates to novel potassium channels and genes encoding these channels. More specifically the invention provides isolated polynucleotides encoding the KCNQ4 potassium channel, cells transformed with these polynucleotides, transgenic animals comprising genetic mutations, and the use of the transformed cells and the transgenic animals for the in vitro and in vivo screening of drugs affecting KCNQ4 containing potassium channels.
DK00901048T 1999-01-26 2000-01-19 New potassium channels and genes encoding these potassium channels DK1147134T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA199900076 1999-01-26
DKPA199900693 1999-05-19
PCT/DK2000/000024 WO2000044786A1 (en) 1999-01-26 2000-01-19 Novel potassium channels and genes encoding these potassium channels

Publications (1)

Publication Number Publication Date
DK1147134T3 true DK1147134T3 (en) 2007-02-05

Family

ID=26063256

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00901048T DK1147134T3 (en) 1999-01-26 2000-01-19 New potassium channels and genes encoding these potassium channels

Country Status (7)

Country Link
EP (1) EP1147134B1 (en)
JP (1) JP4711512B2 (en)
AT (1) ATE342279T1 (en)
AU (1) AU2092700A (en)
DE (1) DE60031241T2 (en)
DK (1) DK1147134T3 (en)
WO (1) WO2000044786A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649371B1 (en) * 1999-06-11 2003-11-18 Neurosearch A/S Potassium channel KCNQ5 and sequences encoding the same
DE10013732A1 (en) * 2000-03-21 2001-09-27 Aventis Pharma Gmbh New DNA sequence encoding potassium channel KCNQ5, useful in screening for specific modulators, potential agents for treating central nervous system and cardiovascular diseases
US6617131B2 (en) 2000-03-21 2003-09-09 Aventis Pharma Deutschland Gmbh Nucleic acid molecule encoding the potassium channel protein, KCNQ5
CA2412208C (en) * 2000-06-29 2009-08-18 Neurosearch A/S Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators
TWI287984B (en) * 2000-10-17 2007-10-11 Wyeth Corp Pharmaceutical composition for modulating bladder function
WO2002054862A2 (en) * 2000-12-13 2002-07-18 Deltagen Inc TRANSGENIC MICE CONTAINING Kv8.1 POTASSIUM CHANNEL ALPHA SUBUNIT GENE DISRUPTIONS
AR067536A1 (en) 2007-07-17 2009-10-14 Hoffmann La Roche METHOD FOR OBTAINING A MONO-PEGILATED ERYTHROPOYETIN IN A SUBSTANTIALLY HOMOGENOUS FORM
CL2008002053A1 (en) 2007-07-17 2009-05-22 Hoffmann La Roche Method for the purification of a monopeglated erythropoietin (epompeg) which consists of providing a solution containing mono, poly and non-peglated erythropoietin and passing it through two steps of cation exchange chromatography and a method to produce epo mpeg that includes a purification method.
JP5714572B2 (en) * 2009-06-03 2015-05-07 マーケット ユニバーシティー Method of modulating KCNQ potassium channel activity for the treatment of psychiatric disorders and symptoms
WO2020246832A1 (en) * 2019-06-05 2020-12-10 연세대학교 산학협력단 Composition for preventing or treating potassium channelopathy
KR102508681B1 (en) * 2019-06-05 2023-03-13 연세대학교 산학협력단 A Composition for Preventing or Treating Potassium Channelopathies
CA3233097A1 (en) * 2021-09-30 2023-04-06 Katherine Diane GRIBBLE Compositions and methods for treating kcnq4-associated hearing loss

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001519646A (en) * 1995-12-22 2001-10-23 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション Long QT syndrome gene encoding KVLQT1 and its association with minK
WO1999021875A1 (en) * 1997-10-24 1999-05-06 University Of Utah Research Foundation Kcnq2 and kcnq3-potassium channel genes which are mutated in benign familial neonatal convulsions (bfnc) and other epilepsies

Also Published As

Publication number Publication date
JP2002541769A (en) 2002-12-10
DE60031241T2 (en) 2007-02-08
EP1147134A1 (en) 2001-10-24
DE60031241D1 (en) 2006-11-23
AU2092700A (en) 2000-08-18
ATE342279T1 (en) 2006-11-15
WO2000044786A1 (en) 2000-08-03
JP4711512B2 (en) 2011-06-29
EP1147134B1 (en) 2006-10-11

Similar Documents

Publication Publication Date Title
DK1147134T3 (en) New potassium channels and genes encoding these potassium channels
DE60031997D1 (en) UMKEHRTRANSFEKTIONSVERFAHREN
ZA200405388B (en) Binding proteins as biosensors
EP1709195A4 (en) Cell transfecting formulations of small interfering rna, related compositions and methods of making and use
DK1165078T3 (en) Methods for inducing cancer cell death and tumor regression
ATE548391T1 (en) CAPTIVE BINDING PROTEINS AS BIOSENSORS
SI1520008T1 (en) Animal protein free media for cultivation of cells
DE69637156D1 (en) DNA MOLECULE, MANUFACTURE AND USE IN GENE THERAPY
ATE252639T1 (en) MODIFIED FACTOR AFFECTING DORSAL TISSUE
PL336983A1 (en) Compounds, their production and application as carriers of nucleic acids in cells
TR199801395A2 (en) Genetically modified cells and their uses.
ATE374212T1 (en) NEW POTASSIUM CHANNELS AND GENES CODING FOR THEM
DE69935782D1 (en) BREAST CANCER RESISTANT PROTEIN (BCRP) AND FOR THIS ENCODING DNA
IL158147A0 (en) Methods and cells for identifying cancer-related genes
DK1073715T3 (en) Animal cell culture medium containing methionine and its use
AR020779A1 (en) MATERIALS AND METHODS FOR THE MODIFICATION OF THE POLISACARIDS OF THE CELL WALLS OF THE PLANTS
BG105779A (en) Human antibiotic proteins
AR028316A1 (en) NSEA ELEVATED MASS GENE OF CHROMOSOME 11Q13.3
SG146640A1 (en) Isolated photoprotein mtclytin, and use thereof
WO1998025125A3 (en) Predisposition to breast cancer by mutations at the ataxia-telangiectasia genetic locus
TR199802300T2 (en) Use of genetic transformation in a gene in the human G protein 3 subunit for the diagnosis of diseases.
HUP0203801A2 (en) Recombinant adenoviruses preparation and adenovirus banks
DK1634955T3 (en) Conditional gene vectors regulated in cis
WO2003027632A3 (en) Use of isogenic human cancer cells for high-throughput screening and drug discovery
AU2003298014A8 (en) Compositions, splice variants and methods relating to colon specific genes and proteins